Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy.
Arthur MatthysBenjamin BardelFabien Le BrasAlain CréangeTarik NordineRomain GounotSaskia Ingen-Housz-OroMuriel CarvalhoJean-Pascal LefaucheurCorinne HaiounViolaine Planté-BordeneuveThierry GendrePublished in: European journal of neurology (2024)
Brentuximab vedotin-induced neuropathy is an overlooked complication. Based on four easily identifiable "red flags", we provide an algorithm to help non-neurologist physicians that care for BV-treated patients to detect BV-IN. The aim of the algorithm is to decrease the diagnostic and management delay of this disabling neuropathy.
Keyphrases
- hodgkin lymphoma
- end stage renal disease
- newly diagnosed
- machine learning
- ejection fraction
- deep learning
- lps induced
- primary care
- chronic kidney disease
- prognostic factors
- oxidative stress
- high glucose
- peritoneal dialysis
- stem cells
- inflammatory response
- bone marrow
- patient reported outcomes
- drug induced
- neural network
- patient reported
- replacement therapy
- cell therapy
- smoking cessation